The U.S. Food and Drug Administration (FDA) recently announced that the shortage of Eli Lilly's weight loss medications, Mounjaro and Zepbound, has been resolved. While these drugs, which contain tirzepatide, are now more readily available, patients and prescribers might still face occasional local shortages as they move through the supply chain.Mounjaro, which is primarily used for diabetes treatment, and Zepbound, used for weight control, had been listed on the FDA's shortage list since late 2022 and Apri ...